Don't forget
The event is from monday 17th June to tuesday 18th of June
This allows for anyone that want’s to request and join hikes the weekend 15th-16th June to any of the nearby sights and mountains.
37 °C Health Tech 17-18 JUN 19
Health Tech & Life Science Business Conference
Personalised Health - only for rich patients in big cities ?
Panel discussion followed by Q&A the Audience.
17th-18th June, Stavanger
Speakers:
Steinar Thoresen
Medical Director
2013- Medical Director AbbVie Norway
2013-2017 Head R&D Group The Pharma Trade Org Norway
2006-2013 Head of Clinical Research, Medical Director Norway Denmark and Iceland GlaxoSmithKline
1999-2013 Professor ll University of Bergen
1992-2006 Head National Cervical- and Breast-Cancer Screening, The Cancer Registry of Norway
1990-1991 Visiting scientist Harvard Medical School, Boston
1985-1990 Head of Registration, The Cancer Registry of Norway
1979-1984 Pathologist PhD Haukeland University Hospital
2016- Board member Bergen Biomedical
2017- Head OCC Election Committee
Abbvie
Henrik Lund
MD, PhD, CEO
Henrik Lund has a PhD in lipidology, post-doctoral training at UCSF, San Francisco, US. Henrik Lund served 10 years as Medical Director in AstraZeneca with leadership roles in drug development. 2005-2010 Vice President in AstraZeneca Clinical Development, overseeing global clinical trials. From 2010 CEO, Board positions in Norwegian biotechs, 2008-2018 in the Board/Chairman, Oslo Cancer Cluster, NCE. From 2014, CEO of Regenics AS, involved in tissue regeneration/wound treatment. 2017 EU Commision H2020 RIA expert.
Regenics AS
Richa Wilson
Global lead, digital health and neuroscience, Roche Personalized Health Care Pharma Partnering
Richa Wilson is the global lead for digital health and neuroscience in Roche’s Digital and
Personalized Health Care Pharma Partnering at Hoffman-La Roche. Her role is to identify and
develop new strategic partnership opportunities at the nexus of technology and healthcare.
Richa’s passion is to digitise healthcare to improve patient outcomes, and engage patients and
consumers in their health.
Richa joined Roche in 2012 in the Diagnostics division of Roche. Prior to joining Roche, Richa
served in leadership roles in strategy and partnering for start-up biotech companies, venture, the
public sector, and pharma. During her career, she has led many strategic partnerships and
acquisitions.
Richa has a background in science, business and law. She is a registered patent agent and
received her MS from the University of Hawaii, PhD from Rutgers University, and MBA from
Wharton, University of Pennsylvania.
Roche
Sander J. Tufte
Director Industry and Technology
Sander has held various executive positions in international sales and marketing and business
development within the life science industry. He was Marketing Director at Axis-Shield ASA (now
Abbott) within their IVD Point of Care business. Prior to this he worked for Dynal Biotech (now
Thermo Fisher), PhotoCure and AstraZeneca.
From 2005-2010 Sander headed up the Norwegian trade council, Innovation Norway, in Boston,
Mass., helping Norwegian biotechs and medtechs with access to market and risk capital, and
partnering strategies. Currently he works as a Director with the Research Council of Norway in charge
of a portfolio important funding schemes for research and innovation in industry including the R&D
tax incentive scheme SkatteFUNN, Innovation Projects and Regional Research Funds.
Sander holds a BSc Honours graduate from University of Strathclyde in Glasgow, Scotland majoring in
Biotechnology. He also holds an MSc in Financial studies from Strathclyde Business School and an
MBA from Warwick Business School in England.
Research Council of Norway
Relevant issues/questions:
How can personalised medicine be affordable?
ATMPs (point of care...)
Will old fashion and inefficient treatment be phased out?
Only for rich people in big cities?
Further reading
From standard to personalised care
How genomic profiling and data sharing can alter the course of cancer care
“In the future, more patients who receive genomic diagnostic profiling would have a greater choice of approved treatment options for their specific genetic profile.”
Origin unknown
How genomic profiling is shedding light on a poorly understood type of cancer
"The CUPISCO trial is the most exciting development that’s happened for CUP patients,” says Tanya Knott, Director, the Sarah Jennifer Knott Foundation